top of page
Transformative Therapies for Autoimmune Disease​
Discovering New Treatments,
Unlocking Possibilities
ABOUT
WHO WE ARE
Unlocking Possibilities
MonaMar is a discovery stage, biotechnology company dedicated to the development of first-in-class (novel MoA), oral small-molecule, transformative medicines for autoimmune inflammatory diseases where other modalities have fallen short.
​​
MORE ABOUT
First-in-class therapeutics for autoimmune disorders
Differentiated small molecule inhibitors for patient Quality of Life
Potential for significant value generation
bottom of page